First‐in‐human study with intratumoral administration of a CD40 agonistic antibody, ADC‐1013, in advanced solid malignancies von Irenaeus, Sandra M. M., Nielsen, Dorte, Ellmark, Peter, Yachnin, Jeffrey, Deronic, Adnan, Nilsson, Anneli, Norlén, Per, Veitonmäki, Niina, Wennersten, Camilla S., Ullenhag, Gustav J.

Volltext

Bispecific antibodies in cancer immunotherapy von Dahlén, Eva, Veitonmäki, Niina, Norlén, Per

Volltext

The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity von Mangsbo, Sara M, Broos, Sissela, Fletcher, Erika, Veitonmäki, Niina, Furebring, Christina, Dahlén, Eva, Norlén, Per, Lindstedt, Malin, Tötterman, Thomas H, Ellmark, Peter

Volltext

Differential roles of p80- and p130-angiomotin in the switch between migration and stabilization of endothelial cells von Ernkvist, Mira, Birot, Olivier, Sinha, Indranil, Veitonmaki, Niina, Nyström, Staffan, Aase, Karin, Holmgren, Lars

Volltext

Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for K1-5-induced antiangiogenesis von VEITONMÄKI, Niina, RENHAI CAO, WU, Lin-Hua, MOSER, Tammy L, BO LI, PIZZO, Salvatore V, ZHIVOTOVSKY, Boris, YIHAI CAO

Volltext

Adiponectin-Induced Antiangiogenesis and Antitumor Activity Involve Caspase-Mediated Endothelial Cell Apoptosis von Bråkenhielm, Ebba, Veitonmäki, Niina, Cao, Renhai, Kihara, Shinji, Matsuzawa, Yuji, Zhivotovsky, Boris, Funahashi, Tohru, Cao, Yihai, Kishimoto, Tadamitsu

Volltext

Therapeutic antibodies targeting angiomotin inhibit angiogenesis in vivo von Levchenko, Tetyana, Veitonmäki, Niina, Lundkvist, Andrea, Gerhardt, Holger, Ming, Yue, Berggren, Kristina, Kvanta, Anders, Carlsson, Roland, Holmgren, Lars

Volltext

The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation von Kvarnhammar, Anne Månsson, Veitonmäki, Niina, Hägerbrand, Karin, Dahlman, Anna, Smith, Karin Enell, Fritzell, Sara, von Schantz, Laura, Thagesson, Mia, Werchau, Doreen, Smedenfors, Kristine, Johansson, Maria, Rosén, Anna, Åberg, Ida, Winnerstam, Magnus, Nyblom, Eva, Barchan, Karin, Furebring, Christina, Norlén, Per, Ellmark, Peter

Volltext

A Human ICAM-1 Antibody Isolated by a Function-First Approach Has Potent Macrophage-Dependent Antimyeloma Activity In Vivo von Veitonmäki, Niina, Hansson, Markus, Zhan, Fenghuang, Sundberg, Annika, Löfstedt, Tobias, Ljungars, Anne, Li, Zhan-Chun, Martinsson-Niskanen, Titti, Zeng, Ming, Yang, Ye, Danielsson, Lena, Kovacek, Mathilda, Lundqvist, Andrea, Mårtensson, Linda, Teige, Ingrid, Tricot, Guido, Frendéus, Björn

Volltext

The Epitope Targeted by Apoptosis-Inducing ICAM-1 Antibody B11 Is Highly Expressed in Multiple Myeloma von Hansson, Markus, Veitonmäki, Niina, Lindblom, Anders, Frendéus, Björn

Volltext

Angiomotin Regulates Endothelial Cell-Cell Junctions and Cell Motility von Bratt, Anders, Birot, Olivier, Sinha, Indranil, Veitonmäki, Niina, Aase, Karin, Ernkvist, Mira, Holmgren, Lars

Volltext

A DNA Vaccine Targeting Angiomotin Inhibits Angiogenesis and Suppresses Tumor Growth von Holmgren, Lars, Ambrosino, Elena, Birot, Olivier, Tullus, Carl, Veitonmäki, Niina, Levchenko, Tetyana, Carlson, Lena-Maria, Musiani, Piero, Iezzi, Manuela, Curcio, Claudia, Forni, Guido, Cavallo, Federica, Kiessling, Rolf

Volltext

p130‐Angiomotin associates to actin and controls endothelial cell shape von Ernkvist, Mira, Aase, Karin, Ukomadu, Chinwe, Wohlschlegel, James, Blackman, Ryan, Veitonmäki, Niina, Bratt, Anders, Dutta, Anindya, Holmgren, Lars

Volltext

Abstract 4569: Cell death-inducing ICAM-1 antibody has broad and potent anti-myeloma activity in vivo von Veitonmaki, Niina, Hansson, Markus, Li, Zhan-chun, Ljungars, Anne, Danielsson, Lena, Bjorn, Frendeus

Volltext

Suppression of Angiogenesis and Tumor Growth by the Inhibitor K1-5 Generated by Plasmin-Mediated Proteolysis von Cao, Renhai, Wu, Hua-Lin, Veitonmäki, Niina, Linden, Philip, Farnebo, Jacob, Shi, Guey-Yueh, Cao, Yihai

Volltext

Abstract 3251: Fibroblast activation protein (FAP)-selective delivery of CD40 agonistic DARPin®molecule for tumor-localized immune activation von Rigamonti, Nicolo, Schlegel, Anja, Barsin, Sophie, Schwestermann, Jonas, Mangold, Susanne, Kaufmann, Yvonne, Zitt, Christof, Veitonmäki, Niina, Levitsky, Victor, Metz, Clara

Volltext

COMBINATION THERAPIES WITH ANTI CD40 ANTIBODIES von Norlen, Per, Ellmark, Peter, Veitonmaki, Niina

Volltext bestellen

COMBINATION THERAPIES WITH ANTI CD40 ANTIBODIES von Norlen, Per, Ellmark, Peter, Veitonmaki, Niina

Volltext bestellen

The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies von Nelson, Michelle H, Fritzell, Sara, Miller, Robert, Werchau, Doreen, Van Citters, Danielle, Nilsson, Anneli, Misher, Lynda, Ljung, Lill, Bader, Robert, Deronic, Adnan, Chunyk, Allison G, Schultz, Lena, Varas, Laura A, Rose, Nadia, Håkansson, Maria, Gross, Jane, Furebring, Christina, Pavlik, Peter, Sundstedt, Anette, Veitonmäki, Niina, Ramos, Hilario J, Säll, Anna, Dahlman, Anna, Bienvenue, David, von Schantz, Laura, McMahan, Catherine J, Askmyr, Maria, Hernandez-Hoyos, Gabriela, Ellmark, Peter

Volltext

A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression von Rigamonti, Nicolò, Veitonmäki, Niina, Domke, Clara, Barsin, Sophie, Jetzer, Sarah, Abdelmotaleb, Omar, Bessey, Ralph, Lekishvili, Tamara, Malvezzi, Francesca, Gachechiladze, Mariam, Behe, Martin, Levitsky, Victor, Trail, Pamela A

Volltext